arrow_back Back to App

Protecting Genetic Data: Mandatory Review of Foreign Investments in DNA Companies.

This law mandates strict government review for foreign investments in U.S. businesses that collect or maintain genetic information of U.S. citizens, including genomic sequencing data. The goal is to safeguard sensitive health data from foreign acquisition, enhancing national security. The Secretary of Health must now be consulted during these reviews.
Key points
Foreign investments in companies holding U.S. citizens' genetic data (like DNA test results) must undergo mandatory national security review by the government committee (CFIUS).
The Secretary of Health and Human Services must be consulted during the review of these transactions to ensure proper assessment of medical data risks.
Congressional oversight of the investment review process is expanded, involving intelligence and foreign affairs committees.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_1827
Sponsor: Sen. Rubio, Marco [R-FL]
Process start date: 2023-06-06
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

GENE Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_1827.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2023-06-06.

What are the main provisions?

Key points include:

  • Foreign investments in companies holding U.S. citizens' genetic data (like DNA test results) must undergo mandatory national security review by the government committee (CFIUS).
  • The Secretary of Health and Human Services must be consulted during the review of these transactions to ensure proper assessment of medical data risks.
  • Congressional oversight of the investment review process is expanded, involving intelligence and foreign affairs committees.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Rubio, Marco [R-FL].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

CATEGORIES

Security Health Economy